Back to all announcements

DJ Ananda Developments Plc hapac® Update

12 June 2019 
                            ANANDA DEVELOPMENTS PLC 
                          ("Ananda" or the "Company") 
                                 hapac® Update 
The directors of Ananda Developments PLC (NEX: ANA) are pleased to provide 
shareholders with the following update regarding hapac®. 
Ananda owns 15% of Liberty Herbal Technologies Limited, the 100% owner of hapac 
®, a technology for inhaling medicinal cannabis. 
As previously announced, the hapac® product was launched in Milan, Italy over 
the Christmas and New Year period 2018/2019.    Since the last update in April 
*             hapac® continues to be sold in 6 stores in Italy 
*             hapac® products have been launched online on the Easyjoint e-shop 
*             A new range of products have been developed and launched 
*             Sales have increased significantly since January 2019 
*             Plans are in place to launch a website and 
e-shop and further expand distribution. 
Further information on the hapac® product can be found at 
The directors of the Company accept responsibility for the contents of this 
Ananda Developments PLC                                 +44 (0)7392 696 517 
Chief Executive Officer 
Melissa Sturgess 
Investor Relations 
Jeremy Sturgess-Smith 
Peterhouse Capital Limited                              +44 (0)20 7469 0930 
Corporate Finance 
Mark Anwyl 
Fungai Ndoro 
Corporate Broking 
Lucy Williams 
Duncan Vasey 
Notes to editors 
About Ananda Developments PLC 
Ananda Developments invests in the developing market for medical or therapeutic 
Cannabis derivatives, or related products, including but not limited to 
nutraceuticals, dietary supplements and cosmetic products which contain 
Cannabis or hemp derived cannabinoids. The Directors believe that this market 
is growing due to an increasing number of states in the USA, as well as other 
countries around the world, changing their laws to allow for products 
containing constituents of Medical Cannabis to be developed, approved and sold. 
A copy of the Company's Admission Document is available at 
Ananda's investment strategy is to invest in companies, projects or products 
that are progressing medical or therapeutic Cannabis research and development, 
or seeking to produce or cultivate Cannabis in any jurisdiction in which it is 
legal to do so, or are developing or have already developed, products that 
contain Cannabis derived cannabinoids and require funding to progress work 
plans or commercialise products. 

(END) Dow Jones Newswires

June 12, 2019 02:01 ET (06:01 GMT)